Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram

被引：12

作者：

Fernandez Montes, A. ^{[1
]}

Vazquez Rivera, F. ^{[2
]}

Martinez Lago, N. ^{[3
]}

Covela Rua, M. ^{[4
]}

Cousillas Castineiras, A. ^{[5
]}

Gonzalez Villarroel, P. ^{[6
]}

De la Camara Gomez, J. ^{[7
]}

Mendez Mendez, J. C. ^{[8
]}

Salgado Fernandez, M. ^{[9
]}

Candamio Folgar, S. ^{[10
]}

Reboredo Lopez, M. ^{[11
]}

Carmona Campos, M. ^{[12
]}

Gallardo Martin, E. ^{[13
]}

Jorge Fernandez, M. ^{[14
]}

Pellon Augusto, M. L. ^{[15
]}

Paris Bouzas, L. ^{[16
]}

Garcia Gomez, J. ^{[17
]}

机构：

[1] Complexo Hosp Univ Ourense, Med Oncol Dept, C Calle Ramon Puga Noguerol, 54, S-N, E-32005 Orense, Spain

[2] Hosp Clin Univ Santiago, Med Oncol Dept, Rua Choupana, S-N, E-15706 Santiago, Spain

[3] Hosp Univ A Coruna, Med Oncol Dept, C As Xubias, S-N, E-15006 La Coruna, Spain

[4] Hosp Univ Lucus Augusti, Med Oncol Dept, C Dr Ulises Romero, 1, E-27003 Lugo, Spain

[5] Hosp Prov Pontevedra, Med Oncol Dept, C Loureiro Crespo, 2, E-36002 Pontevedra, Spain

[6] Hosp Univ Alvaro Cunqueiro, Med Oncol Dept, C Estrada Clara Campoamor, 341, E-36312 Vigo, Pontevedra, Spain

[7] Hosp Univ Arquitecto Marcide, Med Oncol Dept, Av Residencia, S-N, E-15405 Ferrol, A Coruna, Spain

[8] Ctr Onclg Galicia, Med Oncol Dept, Rua Doctor Camilo Veiras, 1, E-15009 La Coruna, Spain

[9] Complexo Hosp Univ Ourense, Med Oncol Dept, C Ramon Puga, S-N, E-32005 Orense, Spain

[10] Hosp Clin Univ Santiago, Med Oncol Dept, Rua Choupana, S-N, E-15706 Santiago, A Coruna, Spain

[11] Hosp Univ Coruna, Med Oncol Dept, C As Xubias, S-N, E-15006 La Coruna, Spain

[12] Hosp Univ Lucus Augusti, Med Oncol Dept, C Dr Ulises Romero, 1, E-27003 Lugo, Spain

[13] Hosp Prov Pontevedra, Med Oncol Dept, C Loureiro Crespo, 2, E-36002 Pontevedra, Spain

[14] Hosp Univ Alvaro Cunqueiro, Med Oncol Dept, C Estrada Clara Campoamor, 341, E-36312 Vigo, Pontevedra, Spain

[15] Hosp Univ Arquitecto Marcide, Med Oncol Dept, Av Residencia, S-N, E-15405 Ferrol, A Coruna, Spain

[16] Ctr Onclg Galicia, Med Oncol Dept, Rua Doctor Camilo Veiras, 1, E-15009 La Coruna, Spain

[17] Complexo Hosp Univ Ourense, Med Oncol Dept, C Calle Ramon Puga Noguerol, S-N, E-32005 Orense, Spain

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2020年 / 22卷 / 03期

关键词：

Real-life; Metastatic colorectal cancer; Refractory; Trifluridine; tipiracil; Prognostic factors; Nomogram; 1ST-LINE TREATMENT; PHASE-I; TAS-102; FLUOROURACIL; ANTIMETABOLITE; NEUTROPENIA; MONOTHERAPY; MULTICENTER; LEUCOVORIN; GUIDELINES;

D O I：

10.1007/s12094-019-02130-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction Trifluridine/tipiracil combination has shown a benefit over placebo in the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC). We evaluated the efficacy and safety of this combination in the real-life setting at eight Galician centers in Spain. Patients and methods This is a retrospective study of a cohort of patients with mCRC in treatment with trifluridine/tipiracil within usual clinical practice who have been previously treated or are not considered candidates for treatment with available therapies. Results A total of 160 mCRC patients were included. Our data showed that 11.9% of patients achieved disease control. Median progression-free survival was 2.75 months; at 5.66 months follow-up, median overall survival was 7.94 months. Asthenia and neutropenia (48.1% both) were the most frequent adverse events. Overall survival was lower in patients with ECOG 2, multiple metastatic sites, platelets count 350,000/mu l, alkaline phosphatase > 500 IU/l, and carcinoembryonic antigen > 10 ng/ml. Conclusion The results of this study confirm the efficacy and safety of trifluridine/tipiracil in chemorefractory mCRC patients. However, patients in clinical practice differ from patients in clinical trials. Due to this, prognostic factors have special importance to offer the best therapeutic approach.

引用

页码：351 / 359

页数：9

共 37 条

[1]

American Cancer Society, 2018, FACTS FIG 2011 2013

[2]

[Anonymous], 2018, PRODUCT INFORM TRIFL

[3]

[Anonymous], 2017, ANN ONCOL S5

[4]

[Anonymous], 2018, PRODUCT INFORM REGOR

[5]

[Anonymous], 2006, P AM SOC CLIN ONCOL

[6] A retrospective study of trifluridine/tipiracil in pretreated metastatic colorectal cancer patients in clinical practice [J].

Borelli, Beatrice ;

Zucchelli, Gemma ;

Rossini, Daniele ;

Cremolini, Chiara ;

Antoniotti, Carlotta ;

Moretto, Roberto ;

Marmorino, Federica ;

Colombo, Camilla ;

Vannini, Francesca ;

Delliponti, Laura ;

Spione, Mario ;

Ongaro, Elena ;

Masi, Gianluca ;

Brunetti, Isa Maura ;

Pfanner, Elisabetta ;

Salvatore, Lisa ;

Falcone, Alfredo .

COLORECTAL CANCER, 2018, 7 (01)

[7] Treatment Decisions After Diagnosis of Metastatic Colorectal Cancer [J].

Cartwright, Thomas H. .

CLINICAL COLORECTAL CANCER, 2012, 11 (03) :155-166

[8] SEOM Clinical guidelines for the treatment of advanced colorectal cancer 2013 [J].

Casado-Saenz, E. ;

Feliu, J. ;

Gomez-Espana, M. A. ;

Sanchez-Gastaldo, A. ;

Garcia-Carbonero, R. .

CLINICAL & TRANSLATIONAL ONCOLOGY, 2013, 15 (12) :996-1003

[9] Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].

de Gramont, A ;

Figer, A ;

Seymour, M ;

Homerin, M ;

Hmissi, A ;

Cassidy, J ;

Boni, C ;

Cortes-Funes, H ;

Cervantes, A ;

Freyer, G ;

Papamichael, D ;

Le Bail, N ;

Louvet, C ;

Hendler, D ;

de Braud, F ;

Wilson, C ;

Morvan, F ;

Bonetti, A .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947

[10] Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].

Douillard, JY ;

Cunningham, D ;

Roth, AD ;

Navarro, M ;

James, RD ;

Karasek, P ;

Jandik, P ;

Iveson, T ;

Carmichael, J ;

Alakl, M ;

Gruia, G ;

Awad, L ;

Rougier, P .

LANCET, 2000, 355 (9209) :1041-1047

← 1 2 3 4 →